Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP: RHHVF )

312.59 +4.50 (+1.46%)
Streaming Delayed Price Updated: 12:30 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 7 Next >
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
Via Benzinga
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
Via Benzinga
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Via Benzinga
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
Via Benzinga
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
Via Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
Via Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
Via Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
Via Benzinga
Roche's Follicular Lymphoma Therapy Scores FDA Approval
Via Benzinga
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
Via Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
Via Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
Via Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
Via Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
Via Benzinga
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
Via Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
Via Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.